For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ulm D-89081
0 studies enrolling now · 13 studies all time
What they study most
Alzheimer's Disease, Carcinoma, Non-Small-Cell Lung, Diabetic Macular Edema, Diabetic Retinopathy, Major Depressive Disorder, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Non-small Cell Lung Cancer, Relapsing-Remitting Multiple Sclerosis
Studies at this site
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy — Completed
- A Study in Non-Small Cell Lung Cancer — Completed
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants — Completed
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
- Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer — Completed
- A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) — Completed
- A Study in the Treatment of Children and Adolescents With Major Depressive Disorder — Completed
- Reduction in the Occurrence of Center-Involved Diabetic Macular Edema — Completed
- Effect of Ruboxistaurin on Clinically Significant Macular Edema — Completed
- Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer — Completed
- Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) — Completed